243 related articles for article (PubMed ID: 27264717)
41. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation.
Zhu B; Zhang H; Yu L
Biomed Pharmacother; 2017 Feb; 86():547-554. PubMed ID: 28024291
[TBL] [Abstract][Full Text] [Related]
42. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
43. Design, preparation, and in vitro characterization of a trimodally-targeted nanomagnetic onco-theranostic system for cancer diagnosis and therapy.
Zarrin A; Sadighian S; Rostamizadeh K; Firuzi O; Hamidi M; Mohammadi-Samani S; Miri R
Int J Pharm; 2016 Mar; 500(1-2):62-76. PubMed ID: 26721723
[TBL] [Abstract][Full Text] [Related]
44. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
45. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy.
Han Y; Zhang P; Chen Y; Sun J; Kong F
Int J Mol Med; 2014 Jul; 34(1):191-6. PubMed ID: 24804644
[TBL] [Abstract][Full Text] [Related]
46. Preparation, characterization, and in vivo evaluation of doxorubicin loaded BSA nanoparticles with folic acid modified dextran surface.
Hao H; Ma Q; Huang C; He F; Yao P
Int J Pharm; 2013 Feb; 444(1-2):77-84. PubMed ID: 23370437
[TBL] [Abstract][Full Text] [Related]
47. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration.
Xu X; Li J; Han S; Tao C; Fang L; Sun Y; Zhu J; Liang Z; Li F
Eur J Pharm Sci; 2016 Jun; 88():178-90. PubMed ID: 26965003
[TBL] [Abstract][Full Text] [Related]
48. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
49. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy.
Wu G; Wang Z; Bian X; Du X; Wei C
Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652
[TBL] [Abstract][Full Text] [Related]
50. Folate-decorated maleilated pullulan-doxorubicin conjugate for active tumor-targeted drug delivery.
Zhang H; Li F; Yi J; Gu C; Fan L; Qiao Y; Tao Y; Cheng C; Wu H
Eur J Pharm Sci; 2011 Apr; 42(5):517-26. PubMed ID: 21352909
[TBL] [Abstract][Full Text] [Related]
51. Constructing transferrin receptor targeted drug delivery system by using doxorubicin hydrochloride and vanadocene dichloride.
Zhang Y; Xiang J; Liu Y; Zhang X; Tang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5982-6. PubMed ID: 21862329
[TBL] [Abstract][Full Text] [Related]
52. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.
Tinkov S; Winter G; Coester C; Bekeredjian R
J Control Release; 2010 Apr; 143(1):143-50. PubMed ID: 20060861
[TBL] [Abstract][Full Text] [Related]
53. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
54. Self-organized nanoparticles based on chitosan-folic acid and dextran succinate-doxorubicin conjugates for drug targeting.
Lee KD; Choi SH; Kim DH; Lee HY; Choi KC
Arch Pharm Res; 2014 Dec; 37(12):1546-53. PubMed ID: 25280540
[TBL] [Abstract][Full Text] [Related]
55. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes.
Gao JQ; Lv Q; Li LM; Tang XJ; Li FZ; Hu YL; Han M
Biomaterials; 2013 Jul; 34(22):5628-39. PubMed ID: 23628475
[TBL] [Abstract][Full Text] [Related]
56. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
57. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
58. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
59. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
60. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Cui T; Zhang S; Sun H
Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]